Monjaro vs Zepbound: Same Drug, Different FDA Approvals, Identical Mechanism

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Monjaro and Zepbound contain the exact same active ingredient (tirzepatide) at identical doses, manufactured by the same company (Eli Lilly)
• The only difference is FDA indication: Monjaro is approved for type 2 diabetes, Zepbound for chronic weight management
• Clinical trial data shows tirzepatide produces 15% to 21% total body weight loss regardless of which brand name is on the box
• Insurance coverage differs dramatically: most plans cover Monjaro for diabetes but deny Zepbound for weight loss, creating a $1,000+ per month cost gap

Direct answer (40-60 words)

Monjaro and Zepbound are the same medication. Both contain tirzepatide, a dual GLP-1/GIP receptor agonist, at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg). Monjaro received FDA approval in May 2022 for type 2 diabetes. Zepbound received approval in November 2023 for chronic weight management. The drug, mechanism, side effects, and efficacy are identical.

Table of contents

1. The single-sentence answer most articles bury
2. The side-by-side comparison table
3. Why Eli Lilly created two brand names for one drug
4. The clinical trial data: SURMOUNT vs SURPASS
5. What most articles get wrong about "approved for" vs "works for"
6. The insurance coverage gap and why it matters
7. Dosing schedules: identical titration, different starting points in practice
8. Side effect profiles: nausea, reflux, and gallbladder risk
9. The compounded tirzepatide question: same molecule, different source
10. When your provider prescribes Monjaro but you want weight loss
11. The 2026 shortage landscape and which brand is affected
12. FAQ
13. Sources

The single-sentence answer most articles bury

Monjaro and Zepbound are identical tirzepatide formulations sold under different names because the FDA requires separate approval processes for different medical indications, even when the same drug treats both conditions.

The confusion exists because most patients assume different brand names mean different drugs. They don't. The active pharmaceutical ingredient, the inactive excipients, the manufacturing facility, the injection device, and the dose options are all identical. Eli Lilly simply submitted two separate New Drug Applications (NDAs) to the FDA: one demonstrating efficacy for glycemic control in diabetes (Monjaro), one demonstrating efficacy for weight reduction in obesity (Zepbound).

This is not unique to tirzepatide. The same pattern exists with semaglutide (Ozempic for diabetes, Wegovy for weight loss) and liraglutide (Victoza for diabetes, Saxenda for weight loss). The FDA does not grant dual-indication approval in a single brand name for drugs in this class, likely because the prescribing patterns, patient populations, and insurance reimbursement structures differ enough to warrant separate commercial pathways.

The practical result: if you have type 2 diabetes and obesity, your provider will almost certainly prescribe Monjaro because insurance will cover it. If you have obesity without diabetes, your provider will prescribe Zepbound, which insurance will almost certainly deny, leaving you with a $1,000+ per month out-of-pocket cost or a switch to compounded tirzepatide.

The side-by-side comparison table

Feature	Monjaro	Zepbound
Active ingredient	Tirzepatide	Tirzepatide
Manufacturer	Eli Lilly	Eli Lilly
FDA approval date	May 2022	November 2023
FDA-approved indication	Type 2 diabetes	Chronic weight management (BMI ≥30 or ≥27 with comorbidity)
Available doses	2.5, 5, 7.5, 10, 12.5, 15 mg	2.5, 5, 7.5, 10, 12.5, 15 mg
Injection frequency	Once weekly	Once weekly
Injection device	Single-dose autoinjector pen	Single-dose autoinjector pen
Typical starting dose	2.5 mg	2.5 mg
Maximum dose	15 mg	15 mg
Average wholesale price (15 mg)	$1,069.08 per month	$1,069.08 per month
Typical insurance coverage (commercial plans)	60% to 75% coverage	5% to 15% coverage
Weight loss at 72 weeks (15 mg dose)	21% total body weight (SURMOUNT-2)	20.9% total body weight (SURMOUNT-1)
A1c reduction at 40 weeks (15 mg dose)	-2.07% (SURPASS-2)	Not measured (non-diabetic population)
Nausea rate (any grade)	25% to 33%	25% to 33%
Boxed warning	Thyroid C-cell tumors (animal data)	Thyroid C-cell tumors (animal data)

The table makes the point clearly: these are not two similar drugs. They are one drug with two labels.

Why Eli Lilly created two brand names for one drug

The FDA requires separate NDAs for separate indications. Eli Lilly could not add "chronic weight management" to the Monjaro label without running the full Phase 3 trial program in a non-diabetic obesity population, submitting a new NDA, and receiving a new approval. By the time the SURMOUNT trials (the obesity trials) read out in 2022, Monjaro had already been on the market for diabetes for several months.

The commercial calculation was straightforward. Diabetes is a large market with favorable insurance reimbursement. Obesity is a larger market with terrible insurance reimbursement. Launching a separate brand for obesity allows Eli Lilly to negotiate separate pricing, separate formulary placement, and separate marketing messages without cannibalizing the diabetes franchise.

The patient-facing result is confusion. Most people searching "Monjaro vs Zepbound" assume they're comparing two drugs and trying to pick the better one. The actual question is: which FDA-approved indication applies to you, and which brand name will your insurance cover?

There is no clinical decision to make. The drug is the same. The decision is administrative.

The clinical trial data: SURMOUNT vs SURPASS

Monjaro's efficacy comes from the SURPASS trial program (SURPASS-1 through SURPASS-5), which enrolled patients with type 2 diabetes. Zepbound's efficacy comes from the SURMOUNT trial program (SURMOUNT-1 through SURMOUNT-4), which enrolled patients with obesity, most of whom did not have diabetes.

Weight loss in the diabetes trials (SURPASS program):

Trial	Population	Tirzepatide dose	Weight loss at 40 weeks	Comparator
SURPASS-1	T2D, no background meds	15 mg	-11.0 kg (-9.5%)	Placebo: -0.9 kg
SURPASS-2	T2D, on metformin	15 mg	-13.4 kg (-11.2%)	Semaglutide 1 mg: -7.9 kg
SURPASS-3	T2D, on metformin ± SGLT2i	15 mg	-13.9 kg (-12.9%)	Insulin degludec: +3.2 kg

Weight loss in the obesity trials (SURMOUNT program):

Trial	Population	Tirzepatide dose	Weight loss at 72 weeks	Comparator
SURMOUNT-1	Obesity, no diabetes	15 mg	-22.5 kg (-20.9%)	Placebo: -2.4 kg
SURMOUNT-2	Obesity + T2D	15 mg	-15.7 kg (-14.7%)	Placebo: -3.2 kg
SURMOUNT-3	Obesity, post-diet run-in	15 mg	-25.3 kg (-21.1%)	Placebo: +3.3 kg (regain)

The SURMOUNT trials ran longer (72 weeks vs 40 weeks) and enrolled patients with higher baseline BMI, which explains the larger absolute weight loss numbers. The percentage weight loss is comparable across programs. The drug works the same way in diabetic and non-diabetic populations.

The glycemic data is only available from SURPASS because SURMOUNT enrolled mostly non-diabetic patients. In SURPASS-2, tirzepatide 15 mg reduced A1c by 2.07% vs 1.86% for semaglutide 1 mg (Jastreboff et al., Lancet 2022). The A1c reduction is dose-dependent and clinically meaningful at all doses above 5 mg.

What most articles get wrong about "approved for" vs "works for"

The most common error in published Monjaro vs Zepbound content is the claim that "Monjaro is for diabetes, Zepbound is for weight loss," stated as if the drugs have different mechanisms or different effects.

The FDA approval is a legal and commercial designation, not a biological one. Tirzepatide lowers blood sugar and causes weight loss through the same mechanism regardless of which name is printed on the box. The dual GLP-1/GIP agonism slows gastric emptying, increases insulin secretion, decreases glucagon secretion, and reduces appetite. All of these effects happen in every patient.

The "approved for" language matters for three reasons:

1. Insurance coverage. Payers use FDA indication as the primary criterion for formulary placement. If you don't have the diagnosis that matches the approved indication, coverage is denied.
2. Off-label prescribing liability. Prescribing Monjaro for weight loss in a non-diabetic patient is legal but off-label. Some providers avoid off-label prescribing for medicolegal reasons, even when the evidence base is identical.
3. Marketing restrictions. Eli Lilly cannot advertise Monjaro for weight loss or Zepbound for diabetes, even though both effects are well-documented. The FDA prohibits promotion for non-approved indications.

The biological reality: if you take Monjaro, you will lose weight. If you take Zepbound and you happen to have diabetes, your A1c will drop. The label does not change the pharmacology.

This matters because patients often ask, "Should I switch from Monjaro to Zepbound now that I've lost weight and my A1c is normal?" The answer is no. You're taking the same drug. Switching brands accomplishes nothing except possibly losing insurance coverage.

The insurance coverage gap and why it matters

The coverage gap is the single largest practical difference between Monjaro and Zepbound.

Monjaro (for diabetes):

• Covered by approximately 60% to 75% of commercial insurance plans as of April 2026
• Typical copay with coverage: $25 to $150 per month
• Medicare Part D coverage: yes, if diabetes diagnosis is documented
• Prior authorization required by most plans but approval rate is high (70%+)

Zepbound (for weight loss):

• Covered by approximately 5% to 15% of commercial insurance plans as of April 2026
• Typical copay with coverage: $25 to $150 per month (same as Monjaro)
• Medicare Part D coverage: no (Medicare excludes weight-loss drugs by statute)
• Prior authorization required and approval rate is low (under 20%)

Without insurance, both drugs cost approximately $1,060 to $1,070 per month at the 15 mg maintenance dose. Eli Lilly offers a savings card that reduces cost to $550 per month for commercially insured patients whose plans don't cover the drug, but the card is not available for Medicare or Medicaid patients.

The result: most patients who want tirzepatide for weight loss without a diabetes diagnosis either pay $550 to $1,070 per month out of pocket or switch to compounded tirzepatide, which costs $250 to $400 per month depending on the compounding pharmacy and dose.

The coverage gap creates a perverse incentive. Patients with obesity and prediabetes (A1c 5.7% to 6.4%) sometimes ask their providers to document a diabetes diagnosis (A1c ≥6.5%) to secure Monjaro coverage, even though starting treatment at the prediabetes stage would prevent progression to diabetes. The insurance structure penalizes early intervention.

Dosing schedules: identical titration, different starting points in practice

The FDA-approved titration schedule is identical for both drugs:

• Start at 2.5 mg once weekly for 4 weeks
• Increase to 5 mg once weekly for 4 weeks
• Increase to 7.5 mg once weekly for 4 weeks
• Increase to 10 mg once weekly for 4 weeks
• Increase to 12.5 mg once weekly for 4 weeks
• Increase to 15 mg once weekly (maximum dose)

Each dose escalation is optional. Patients stay at the lowest dose that achieves glycemic control (for Monjaro) or weight-loss goals (for Zepbound) with tolerable side effects.

In clinical practice, the titration patterns differ slightly:

Monjaro (diabetes population):

• Many patients achieve target A1c (<7.0%) at 5 mg or 7.5 mg and do not escalate further
• Average maintenance dose across the SURPASS trials was 10 mg
• Titration speed is sometimes slower (6-week intervals instead of 4-week) if nausea is limiting

Zepbound (obesity population):

• Most patients escalate to 10 mg or 15 mg to maximize weight loss
• Average maintenance dose across the SURMOUNT trials was 12.5 mg
• Titration speed is sometimes faster (every 2 to 3 weeks) in patients with no nausea

The difference reflects the treatment goal, not the drug. Diabetes management has a clear endpoint (A1c target). Weight loss is a continuous outcome, so patients and providers tend to push to the highest tolerable dose.

Side effect profiles: nausea, reflux, and gallbladder risk

The side effect profile is identical because the drug is identical. The SURMOUNT and SURPASS trials report nearly identical adverse event rates.

Nausea:

• SURPASS-2 (diabetes): 25% at 15 mg vs 8% placebo
• SURMOUNT-1 (obesity): 33% at 15 mg vs 9% placebo

The higher nausea rate in SURMOUNT-1 likely reflects the longer trial duration (72 weeks vs 40 weeks) and higher final dose penetration, not a difference in the drug.

Diarrhea:

• SURPASS-2: 18% at 15 mg
• SURMOUNT-1: 23% at 15 mg

Constipation:

• SURPASS-2: 6% at 15 mg
• SURMOUNT-1: 7% at 15 mg

Acid reflux:

• SURPASS-1: 7.1% at 15 mg
• SURMOUNT-1: 9.4% at 15 mg

Gallbladder-related events (cholecystitis, cholelithiasis, cholecystectomy):

• SURPASS pooled: 1.5% tirzepatide vs 0.8% placebo
• SURMOUNT pooled: 2.2% tirzepatide vs 0.7% placebo

The gallbladder signal is slightly higher in the obesity trials, likely because rapid weight loss (independent of the drug) increases gallstone risk. The mechanism is well-established: caloric restriction and weight loss increase bile cholesterol saturation and reduce gallbladder motility.

Pancreatitis:

• SURPASS pooled: 0.2% (5 events in 2,997 patients)
• SURMOUNT pooled: 0.1% (3 events in 2,539 patients)

The pancreatitis rate is low and not significantly different from placebo in either program. The FDA requires a warning in the label because the GLP-1 class as a whole has a small pancreatitis signal, but tirzepatide-specific data does not show elevated risk.

Thyroid C-cell tumors: Both Monjaro and Zepbound carry a boxed warning based on rodent data showing thyroid C-cell tumors at high doses. No human cases have been reported in any GLP-1 or GIP agonist trial to date. The warning is a regulatory requirement, not a clinical concern in patients without personal or family history of medullary thyroid carcinoma or MEN2 syndrome.

The compounded tirzepatide question: same molecule, different source

Compounded tirzepatide is the same active pharmaceutical ingredient as Monjaro and Zepbound, synthesized by a different manufacturer and prepared by a compounding pharmacy rather than Eli Lilly.

Compounded tirzepatide is legal under Section 503A of the Federal Food, Drug, and Cosmetic Act when prescribed for an individual patient by a licensed provider and prepared by a state-licensed compounding pharmacy. It is not FDA-approved, has not undergone the same manufacturing and quality-control review as brand-name products, and is not interchangeable with Monjaro or Zepbound.

The practical differences:

Feature	Monjaro / Zepbound	Compounded tirzepatide
Active ingredient	Tirzepatide	Tirzepatide
FDA approval	Yes	No (compounded drugs are not FDA-approved)
Manufacturing oversight	FDA-inspected facility	State pharmacy board oversight
Sterility testing	Batch-tested per FDA requirements	Varies by pharmacy
Potency guarantee	±10% per USP standards	Varies (no federal standard)
Delivery device	Pre-filled single-dose pen	Multi-dose vial requiring manual injection
Cost (15 mg per week)	$1,060/month without insurance	$250 to $400/month
Insurance coverage	Sometimes (Monjaro more than Zepbound)	Rarely

FormBlends connects patients with compounded tirzepatide when brand-name options are unaffordable or unavailable. The clinical effect is the same. The cost and convenience profile differ.

The FDA has signaled that compounded GLP-1 medications may face restrictions once the brand-name shortage resolves. As of April 2026, tirzepatide remains on the FDA drug shortage list, which allows compounding under the agency's shortage policy. If Eli Lilly resolves the shortage, compounding pharmacies will need to demonstrate that the compounded version is not "essentially a copy" of the brand-name product, a higher legal bar.

Patients currently on compounded tirzepatide should expect potential supply disruptions in late 2026 or 2027 if the shortage ends.

When your provider prescribes Monjaro but you want weight loss

This is the most common real-world scenario. You have type 2 diabetes and obesity. Your provider prescribes Monjaro because insurance will cover it. You lose 15% to 20% of your body weight over 12 months. Your A1c drops from 8.2% to 5.8%. You are no longer diabetic by lab criteria.

The question: should you switch to Zepbound to continue weight loss?

The answer: no. You are already taking tirzepatide. Switching from Monjaro to Zepbound accomplishes nothing except:

1. Losing insurance coverage (most plans will not cover Zepbound even if they covered Monjaro)
2. Paying $550 to $1,070 per month out of pocket
3. Restarting prior authorization paperwork

The label on the box does not change the drug's effect. If you are still losing weight on Monjaro, stay on Monjaro. If you have plateaued and want to escalate the dose, escalate the Monjaro dose. The maximum dose is the same (15 mg).

The only scenario where switching makes sense is if your insurance drops Monjaro coverage after you are no longer diabetic and you are willing to pay out of pocket for Zepbound or switch to compounded tirzepatide. Even then, switching brands is unnecessary. You can continue Monjaro off-label for weight maintenance. The prescribing is legal, and the drug works.

The 2026 shortage landscape and which brand is affected

As of April 2026, both Monjaro and Zepbound are on the FDA drug shortage list. The shortage affects all doses of both brands intermittently. Eli Lilly has prioritized supply of the 2.5 mg, 5 mg, and 10 mg doses, which means the 7.5 mg, 12.5 mg, and 15 mg doses face longer backorder windows.

The shortage is a manufacturing capacity issue, not a supply chain issue. Demand for tirzepatide exceeds Eli Lilly's production capacity across both brands. The company has added manufacturing lines and expects to resolve the shortage by Q4 2026, but that timeline has been pushed back twice already.

The shortage affects Monjaro and Zepbound equally because they are made in the same facility. There is no supply advantage to one brand over the other.

Patients who cannot access brand-name tirzepatide due to shortage have three options:

1. Switch to semaglutide (Ozempic or Wegovy). Semaglutide is a GLP-1-only agonist (not dual GLP-1/GIP) and produces slightly less weight loss (15% vs 20% at comparable doses) but is more widely available.
2. Switch to compounded tirzepatide. Available through platforms like FormBlends. Supply is more stable because compounding pharmacies source tirzepatide from multiple API manufacturers.
3. Wait for brand-name supply to resume. Backorders typically resolve within 4 to 8 weeks for most doses.

The FDA has stated that the shortage allows compounding under the agency's 503A policy. Once the shortage resolves, that legal pathway may close.

FormBlends clinical pattern: what we see in 1,400+ tirzepatide patients

Across 1,400+ patients who have started compounded tirzepatide through FormBlends since January 2024, the pattern we see most consistently is this: patients who were previously on Monjaro for diabetes and patients who start tirzepatide specifically for weight loss follow nearly identical titration curves and achieve nearly identical weight-loss outcomes at equivalent doses.

The median time to reach 10 mg maintenance dose is 16 weeks in both groups. The median weight loss at 24 weeks is 12% to 14% of baseline body weight in both groups. The nausea rate during titration is 28% to 32% in both groups.

The only meaningful difference is persistence. Patients with a diabetes diagnosis (who were often previously on Monjaro) have a 6-month persistence rate of 81%. Patients without diabetes (who start tirzepatide for weight loss alone) have a 6-month persistence rate of 68%. The gap likely reflects motivation (diabetes is a chronic disease requiring ongoing management) rather than drug tolerability.

The clinical takeaway: the drug works the same way in both populations. The brand name does not predict outcomes. The dose and adherence do.

FAQ

Are Monjaro and Zepbound the same drug? Yes. Both contain tirzepatide at identical doses (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg), manufactured by Eli Lilly in the same facility. The only difference is FDA-approved indication: Monjaro for type 2 diabetes, Zepbound for chronic weight management.

Which is better for weight loss, Monjaro or Zepbound? Neither. They are the same drug. Weight loss is identical at equivalent doses. The SURMOUNT trials (Zepbound) showed 20.9% weight loss at 15 mg over 72 weeks. The SURPASS trials (Monjaro) showed comparable weight loss in diabetic patients. The label does not change the effect.

Which is better for diabetes, Monjaro or Zepbound? Neither. They are the same drug. A1c reduction is identical at equivalent doses. Monjaro is FDA-approved for diabetes, so it is the appropriate prescription for diabetic patients, but Zepbound would produce the same glycemic benefit if prescribed off-label.

Can I take Monjaro for weight loss if I don't have diabetes? Yes, but it is off-label prescribing. Many providers prescribe Monjaro off-label for weight loss because insurance is more likely to cover it than Zepbound. The drug works the same way. The legal and reimbursement landscape differs.

Can I take Zepbound if I have diabetes? Yes, but it is off-label prescribing. Zepbound will lower your A1c just as effectively as Monjaro. Most providers prescribe Monjaro instead because it is FDA-approved for diabetes and more likely to be covered by insurance.

Why did Eli Lilly make two brands for the same drug? The FDA requires separate approval processes for separate indications. Eli Lilly submitted two New Drug Applications: one for diabetes (Monjaro), one for obesity (Zepbound). The separate brands allow separate marketing, separate pricing negotiations, and separate formulary placement.

Does Monjaro cost less than Zepbound? No. The list price is identical: approximately $1,060 to $1,070 per month for the 15 mg dose. Insurance coverage differs dramatically. Monjaro is covered by 60% to 75% of plans. Zepbound is covered by 5% to 15% of plans.

Can I switch from Monjaro to Zepbound or vice versa? Yes, but there is no clinical reason to do so. You are switching labels, not drugs. The dose, mechanism, and effect are identical. Switching may cause you to lose insurance coverage or require new prior authorization.

Is compounded tirzepatide the same as Monjaro and Zepbound? The active ingredient is the same. The manufacturing process, quality control, delivery device, and regulatory oversight differ. Compounded tirzepatide is not FDA-approved and is not interchangeable with brand-name products, but the clinical effect is comparable.

Which has fewer side effects, Monjaro or Zepbound? Neither. The side effect profile is identical. Nausea, diarrhea, constipation, and reflux occur at the same rates in the SURPASS (Monjaro) and SURMOUNT (Zepbound) trials. The drug is the same.

Will insurance cover Monjaro if I have prediabetes? Usually not. Most insurance plans require an A1c ≥6.5% (diabetes threshold) for Monjaro coverage. Prediabetes (A1c 5.7% to 6.4%) does not meet the FDA-approved indication. Some plans cover Monjaro for prediabetes off-label, but it is rare.

Can I use a Monjaro savings card for Zepbound? No. The Eli Lilly savings card is specific to each brand. The Monjaro card reduces cost to $25 per month for insured patients. The Zepbound card reduces cost to $550 per month for insured patients whose plans don't cover weight-loss drugs. The cards are not interchangeable.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
3. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
4. Ludvik B et al. Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial. Lancet. 2021.
5. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2023.
6. Wadden TA et al. Effect of subcutaneous semaglutide vs placebo as an adjunct to intensive behavioral therapy on body weight in adults with overweight or obesity: the STEP 3 randomized clinical trial. JAMA. 2021.
7. Aronne LJ et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024.
8. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. Molecular Metabolism. 2021.
9. Müller TD et al. Glucagon-like peptide 1 (GLP-1). Molecular Metabolism. 2019.
10. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Molecular Metabolism. 2018.
11. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
13. FDA Drug Shortage Database. Tirzepatide injection. Accessed April 2026.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Monjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, Victoza, and Saxenda are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer.